

Int'l. Appln. No.: PCT/EP00/08728

Docket No. B45197

AI
contd
54. A vaccine composition according to claim 49 in which the *Toxoplasma gondii* antigen is SAG1 or TG34.

55. A vaccine composition according to claim 50 in which the *Toxoplasma gondii* antigen is SAG1 or TG34.

56. A vaccine composition according to claim 19 comprising HBsAg antigen and L1, L2, E6, E7, protein D-E6, protein D-E7 or L2-E7 of HPV and optionally in addition one or more of EBVgp 350; VZVgpI; HAV HM-175 inactivated strain; gB685** or pp65 of HCMV and SAG1 or TG34 antigens of *Toxoplasma gondii*.


REMARKS

The above-identified application is being entered into the National Phase from PCT application no. PCT/EP00/08728.

Applicants have cancelled claims 1-18 and added new claims 19-56 to put the claims in conformity with U.S. practice.

No new matter has been introduced.

Respectfully submitted,



Zoltan Kerekes
Attorney for Applicant
Registration No. 38,938

GLAXOSMITHKLINE
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-5024
Facsimile (610) 270-5090
N:\zklapps\b45197\Preliminary Amendment.doc

Int'l. Appln. No.: PCT/EP00/08728
Int'l. Filing Date: 06 September 2000

ABSTRACT

Novel combined vaccine compositions are provided, comprising a hepatitis B viral antigen and optionally in addition one or more of the following: an EBV antigen, a hepatitis A antigen or inactivated attenuated virus, a herpes simplex viral antigen, a VZV antigen, a *Toxoplasma gondii* antigen. The vaccine compositions are formulated with an adjuvant which is a preferential stimulator of TH1 cell response such as 3D-MPL and QS21.